Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single Arm, Phase I/IIa Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation Advanced or Recurrent NSCLC

Next Previous
X
Search
Trial Profile

An Open-label, Single Arm, Phase I/IIa Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation Advanced or Recurrent NSCLC

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezivertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Beta Pharma

    • Most Recent Events

    • 13 Sep 2022 Results assessing efficacy and safety of rezivertinib in treatment-naive patients with locally advanced or metastatic/recurrent EGFR mutated non-small cell lung cancer, presented at the 47th European Society for Medical Oncology Congress.
    • 13 May 2022 Status changed from active, no longer recruiting to completed.
    • 15 Feb 2022 Results (n=172; data cut of date: June 15, 2020) assessing the safety, efficacy and pharmacokinetics of rezivertinib for patients having advanced non-small cell lung cancer with EGFR T790M mutation, published in the Journal of Thoracic Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top